Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and precision medicine. With a market cap of $106.1 billion, Vertex ...

Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts, is a global leader in biotechnology and ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.

BOSTON, January 12, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.